ALLK | AllakosCompany profile
Company profileAllakos is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. Our initial clinical focus is eosinophilic gastritis and/or eosinophilic duodenitis (previously referred to as eosinophilic gastroenteritis), inflammatory diseases of the gastrointestinal tract. We are also conducting clinical trials for other mast cell and eosinophil driven diseases including chronic urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis. Address975 Island Drive Key Persons / Board of Directors
| NotesResearchInvestor pageinvestor.allakos.comIf you are looking for News & events, Press Release, they are available on their Investors Relationssite. Support this projectIf you want to help pay for server cost or for improving this tool. You can send it via Paypal. Social MediaRecommended BooksBuy on Amazon In the world of investing, slow and steady wins the race. With this mantra in mind, trusted author and finance guru Eric Tyson is back with the latest edition of the #1 bestselling book, Investing For Dummies, to help you achieve your investment goals. |